Indogulf Cropsciences Q2 PAT Rises 24% YoY

Revenue from Operations: ₹2,557.78 million (3% increase from ₹2,483.43 million)
Cost of Goods Sold: ₹1,790.06 million (2% increase from ₹1,752.27 million)
Gross Profit: ₹767.72 million (5% increase from ₹731.16 million)
Employee Expense: ₹133.35 million (8% decrease from ₹145.37 million)
Other Expenses: ₹228.75 million (14% decrease from ₹265.70 million)
EBITDA: ₹405.62 million (27% increase from ₹320.09 million)
Finance Cost: ₹40.96 million (11% decrease from ₹45.88 million)
Depreciation & Amortization: ₹28.22 million (8% increase from ₹26.18 million)
Other Income: ₹15.09 million (23% decrease from ₹19.55 million)
PBT (before exceptional items): ₹351.53 million (31% increase from ₹267.58 million)
Exceptional items: ₹0.32 million (91% decrease from ₹3.58 million)
Profit Before Tax: ₹351.85 million (30% increase from ₹271.16 million)
Tax: ₹95.01 million (48% increase from ₹64.31 million)
PAT: ₹256.84 million (24% increase from ₹206.85 million)

Revenue from Operations: ₹4,243.23 million (3% decrease from ₹4,377.15 million)
Cost of Goods Sold: ₹3,009.73 million (7% decrease from ₹3,229.29 million)
Gross Profit: ₹1,233.50 million (7% increase from ₹1,147.86 million)
Employee Expense: ₹270.48 million (1% decrease from ₹272.08 million)
Other Expenses: ₹461.85 million (1% increase from ₹456.47 million)
EBITDA: ₹501.17 million (20% increase from ₹419.31 million)
Finance Cost: ₹86.06 million (3% increase from ₹83.73 million)
Depreciation & Amortization: ₹55.97 million (11% increase from ₹50.50 million)
Other Income: ₹23.94 million (17% decrease from ₹28.88 million)
PBT (before exceptional items): ₹383.08 million (22% increase from ₹313.96 million)
Exceptional items: ₹0.01 million (100% decrease from ₹3.69 million)
Profit Before Tax: ₹383.09 million (21% increase from ₹317.65 million)
Tax: ₹102.11 million (42% increase from ₹72.13 million)
PAT: ₹280.98 million (14% increase from ₹245.52 million)

Equity and Liabilities:

Share capital: ₹632 million (unchanged from FY26)
Other equity: ₹4,244 million (increased from ₹3,961 million)
Total equity: ₹4,876 million (increased from ₹4,593 million)
Total borrowings: ₹2,033 million (₹43 million non-current + ₹1,990 million current) increased from ₹1,769 million (₹30 million non-current + ₹1,739 million current)
Trade payables: ₹1,943 million (increased from ₹1,279 million)
Total liabilities: ₹4,515 million (increased from ₹3,640 million)
Total equity and liabilities: ₹9,391 million (increased from ₹8,234 million)

Assets:

Revenue Mix by Business Verticals (H1 FY27): Crop Protection (85%), Plant Nutrients (5%), Biologicals (6%), Crop Compatibility (4%)
Revenue Mix by End Users: B2C (domestic demand), B2B (184 active institutional partners), Exports
Manufacturing Facilities: Four facilities with total formulation capacity of 42,564 MT/KL and technical manufacturing capacity of 1,360 TPA
Nathupur I, Haryana: 13,500 MT/KL formulation capacity
Barwasni, Haryana: 20,064 MT/KL formulation capacity (expansion underway)
Nathupur II, Haryana: 1,360 TPA technical manufacturing
Samba, Jammu & Kashmir: 9,000 MT/KL formulation capacity

Thailand: Obtained one formulation registration (Spiromesifen 24% SC w/v)
Sri Lanka: Received import permission for Indoapache, field trials commenced for two combination formulations
Brazil: Decision to initiate field trials for Empire and Indoapache, agreement with Brazilian CRO
Recent Export Orders: Successful export of 95 MT of Nutriexc followed by repeat order of 44 MT
Global Registrations: 189 registrations supporting global scalability

Experienced professional team with 30+ years of experience including: